Latest results from an ongoing first-in-human phase 1a/B study of NX5948, a selective bruton's tyrosine kinase (BTK) degrader, in patients with relapsed/refractory CLL and other b-cell malignancies
Authors
Linton, KimCollins, G. P.
Forconi, F.
Shah, N. N.
Dixit, K.
Munir, T.
Omer, Z.
El-Sharkawi, D.
Doorduijn, J.
Alencar, A.
McKay, P.
Riches, J.
Gleeson, M.
Lewis, D.
Winter, A.
Injac, S.
Shih, T.
Nandakumar, S.
Tan, M.
Cherala, G.
Meredith, E.
Danilov, A.
Affiliation
The Christie Hospital and Manchester Cancer Research Centre, Division of Cancer Sciences, Manchester, United KingdomIssue Date
2024